Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Anavex Life Sciences Corp. - Common Stock (NQ: AVXL )

10.87 -0.31 (-2.77%)
Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anavex Life Sciences Corp. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
Preview: Anavex Life Sciences's Earnings
Via Benzinga
Anavex Life Sciences Releases Encouraging Long Term Data From Rett Syndrome Study
Anavex Life Sciences Corp (NASDAQ: AVXL) announced that long-term clinical study results from the U.S. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The Latest Analyst Ratings for Anavex Life Sciences
Via Benzinga
Analyst Ratings for Anavex Life Sciences
Via Benzinga
What's Going On With Anavex Life Sciences Shares Today?
Anavex Life Sciences Corp (NASDAQ: AVXL) shares are trading higher Thursday after the company reported results from its Phase 2 study in patients with Parkinson's disease dementia showing beneficial... 
Via Benzinga
Wall Street Thinks This Small-Cap Stock Can Quadruple in Value
The company generates no revenue, but it may be worth taking a chance on as it possesses lots of upside. 
Via The Motley Fool
This Short-Squeeze Candidate Could Actually Pan Out in the Long Run
Short-sellers have piled into this clinical-stage biopharma stock. 
Via The Motley Fool
Earnings Preview: Anavex Life Sciences
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
Via Benzinga
Here's How Much $100 Invested In Anavex Life Sciences 5 Years Ago Would Be Worth Today
Via Benzinga
Why Shares of Anavex Life Sciences Rose 12.4% in February
The company's first-quarter earnings report detailed positive news regarding its pipeline. 
Via The Motley Fool
Is Anavex Life Sciences Stock a Buy Now?
A short squeeze could be a possibility if the company can prove that bearish investors are wrong about its business. 
Via The Motley Fool
Why Anavex Life Sciences Stock Bolted Higher in January
The biotech's shares have been steadily leaking higher following positive late-stage Alzheimer's disease trial results. 
Via The Motley Fool
Anavex Life Sciences Stock Shows Improved Price Strength Rating
Anavex Life Sciences stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 68 to 75. 
Via Investor's Business Daily
3 Biotech Stocks Under $15 Worth a Second Look in 2023
All three stocks have promising therapies that could drive revenue in the coming years. 
Via The Motley Fool
Top Picks For 2023: Anavex Life Sciences
Anavex is a biopharmaceutical company dedicated to the development of novel drug candidates to treat central nervous system diseases, with encouraging results in Alzheimer’s, Parkinson’s, and Rett... 
Via Talk Markets
Here's How Much You Would Have Made Owning Anavex Life Sciences Stock In The Last 5 Years
Via Benzinga
Tesla To $205? Here Are 10 Other Price Target Changes For Tuesday
Goldman Sachs cut Tesla, Inc. (NASDAQ: TSLA) price target from $235 to $205. Goldman Sachs analyst Mark Delaney maintained a Buy rating on the stock. Tesla shares fell 2.6% to $119.93 in pre-market... 
Via Benzinga
Analyzing Anavex Life Sciences's Short Interest
Anavex Life Sciences's (NASDAQ:AVXL) short percent of float has risen 17.06% since its last report. The company recently reported that it has 11.91 million shares sold short, which is 15.71% of all... 
Via Benzinga
Anavex Life Sciences Stock Could 5x Before 2025 -- Here's Why
The biotech will first need to assuage the concerns of experts by elaborating on its latest clinical trial data. 
Via The Motley Fool
Is Anavex Life Sciences a Buy?
It still needs to prove that its lead program is as effective as it claims for treating Alzheimer's. 
Via The Motley Fool
Is Anavex Life Sciences a Smart Stock to Buy Now?
The company's Alzheimer's disease drug just succeeded in a clinical trial. Or did it? 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For December 6, 2022
Via Benzinga
Dow Drops 100 Points; Asana Shares Plummet
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 100 points on Friday. 
Via Benzinga
Why Cracker Barrel Shares Are Trading Lower By Around 13%? Here Are 42 Stocks Moving In Friday's Mid-Day Session
Gainers Yunhong CTI Ltd. (NASDAQ: CTIB) rose 42% to $0.54 after dipping 56% on Thursday. 
Via Benzinga
Anavex Life Sciences (NASDAQ: AVXL) Says Phase 2b/3 for ANAVEX2-73 Met Primary and Secondary Endpoints Reducing Cognative Decline in Patients with Early Alzheimer’s
Anavex Life Sciences Corp. (NASDAQ: AVXL) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and 
Via Spotlight Growth
Exposures Product Safety
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Gold Down 1%; Samsara Shares Spike Higher
U.S. stocks traded lower midway through trading, with the Dow Jones falling around 75 points on Friday. 
Via Benzinga
Why Anavex Life Sciences Stock Is Surging Today
The biotech reported positive results from a phase 2b/3 study of its lead Alzheimer's disease candidate. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.